摘要
目的:观察阿帕替尼治疗晚期肝癌的疗效及血清LDH水平变化。方法:随机数表法将本院收治的晚期原发性肝细胞癌(HCC)患者54例分为观察组和对照组,各27例。对照组患者接受安慰剂及最佳支持治疗;观察组患者接受口服阿帕替尼治疗。治疗3个月后比较两组患者临床疗效、生存期及不良反应发生情况,并观察血清乳酸脱氢酶(LDH)、甲胎蛋白(AFP)水平变化。结果:治疗3月后,观察组患者ORR和DCR分别为40.74%、85.19%,显著高于对照组的14.81%、55.56%(P<0.05);观察组患者的生存期为(5.43±0.84)月,显著优于对照组的(3.76±0.91)月(P<0.05);两组患者的LDH、AFP水平均较治疗前显著降低(P<0.05),且观察组患者降低幅度明显大于对照组(P<0.05);两组患者各类不良反应发生情况无明显差异(P>0.05)。大部分不良反应为Ⅰ~Ⅱ级,Ⅲ级及以上不良反应情况观察组共11例,对照组共8例,两组比较无明显差异(P>0.05)。结论:晚期HCC患者应用阿帕替尼治疗临床效果满意,可有效降低血清LDH水平,治疗过程中不良反应率较高,需及时对症处理。
Objective: To observe curative effect of apatinib on advanced hepatocellular carcinoma and changes of serum LDH level. Methods: 54 patients with advanced primary hepatocellular carcinoma(HCC)were divided into observation group and control group by random number table method, 27 cases in each group. The control group was given placebo and optimal support treatment. The observation group was given oral apatinib. After 3 months of treatment, clinical curative effect, survival and occurrence of adverse reactions were compared between the two groups. The changes in levels of serum lactate dehydrogenase(LDH)and alpha-fetoprotein(AFP)were observed. Results: After 3 months of treatment, ORR and DCR of observation group were 40.74%and 85.19%, respectively, which were significantly higher than those of control group(14.81%, 55.56%)(P<0.05). The survival of observation group was significantly better than that of control group[(5.43±0.84)months vs(3.76±0.91)months](P<0.05). After treatment, LDH and AFP levels in both groups were significantly decreased(P<0.05). The decrease amplitude in observation group was significantly greater than that in control group(P<0.05). There was no significant difference in occurrence of various adverse reactions between the two groups(P>0.05). Most of the adverse reactions were mainly on grade I-II. There were 11 cases with grade III and above adverse reactions in observation group, and 8 cases in control group(P>0.05). Conclusion: The clinical curative effect of apatinib is satisfactory on patients with advanced HCC, which can effectively reduce serum LDH level. The adverse reaction rate is high in treatment process, and it needs timely symptomatic treatment.
作者
温时来
WEN Shi-lai(Department of Oncology,Ganzhou People’s Hospital,Ganzhou Jiangxi 341000,China)
出处
《药品评价》
CAS
2019年第20期68-69,73,共3页
Drug Evaluation
关键词
阿帕替尼
原发性肝细胞癌
血清乳酸脱氢酶
Apatinib
Primary Hepatocellular Carcinoma
Serum Lactate Dehydrogenase
作者简介
温时来,主治医师,主要从事肿瘤疾病诊疗工作。E-mail:214213456@qq.com。
